Ocugen analyst ratings
Ocugen analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/15/2022 | 323.28% | Roth Capital | → $8 | Reinstates | → Buy |
| 06/02/2022 | 138.1% | Cantor Fitzgerald | → $4.5 | Initiates Coverage On | → Overweight |
| 05/12/2022 | 270.37% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 02/28/2022 | 323.28% | HC Wainwright & Co. | $10 → $8 | Maintains | Buy |
| 06/11/2021 | 217.46% | Roth Capital | $10 → $6 | Downgrades | Buy → Neutral |
| 06/11/2021 | 429.1% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/07/2021 | 482.01% | Cantor Fitzgerald | $15 → $11 | Downgrades | Overweight → Neutral |
| 03/03/2021 | 693.65% | Cantor Fitzgerald | $4 → $15 | Maintains | Overweight |
| 02/09/2021 | 587.83% | Chardan Capital | $0.7 → $13 | Downgrades | Buy → Neutral |
| 02/04/2021 | 138.1% | HC Wainwright & Co. | → $4.5 | Upgrades | Neutral → Buy |
| 11/17/2020 | -47.09% | Roth Capital | → $1 | Initiates Coverage On | → Buy |
| 10/09/2020 | -47.09% | Cantor Fitzgerald | → $1 | Initiates Coverage On | → Overweight |
| 06/03/2020 | -62.96% | Chardan Capital | $2 → $0.7 | Maintains | Buy |
| 06/01/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 12/20/2019 | — | HC Wainwright & Co. | Initiates Coverage On | → Buy | |
| 11/27/2019 | 5.82% | Chardan Capital | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 06/15/2022 | 323.28% | 罗斯资本 | → $8 | 恢复 | →购买 |
| 06/02/2022 | 138.1% | 康托·菲茨杰拉德 | → $4.5 | 开始承保 | →超重 |
| 05/12/2022 | 270.37% | HC Wainwright公司 | $8 → $7 | 维护 | 买 |
| 02/28/2022 | 323.28% | HC Wainwright公司 | $10 → $8 | 维护 | 买 |
| 06/11/2021 | 217.46% | 罗斯资本 | $10 → $6 | 评级下调 | 购买→中性 |
| 06/11/2021 | 429.1% | HC Wainwright公司 | $12 → $10 | 维护 | 买 |
| 05/07/2021 | 482.01% | 康托·菲茨杰拉德 | $15 → $11 | 评级下调 | 超重→中性 |
| 03/03/2021 | 693.65% | 康托·菲茨杰拉德 | $4 → $15 | 维护 | 超重 |
| 02/09/2021 | 587.83% | 查尔丹资本 | $0.7 → $13 | 评级下调 | 购买→中性 |
| 02/04/2021 | 138.1% | HC Wainwright公司 | → $4.5 | 升级 | 中性→购买 |
| 11/17/2020 | -47.09% | 罗斯资本 | → $1 | 开始承保 | →购买 |
| 10/09/2020 | -47.09% | 康托·菲茨杰拉德 | → $1 | 开始承保 | →超重 |
| 06/03/2020 | -62.96% | 查尔丹资本 | $2 → $0.7 | 维护 | 买 |
| 06/01/2020 | — | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 12/20/2019 | — | HC Wainwright公司 | 开始承保 | →购买 | |
| 11/27/2019 | 5.82% | 查尔丹资本 | → $2 | 开始承保 | →购买 |
Ocugen Questions & Answers
Ocugen问答
The latest price target for Ocugen (NASDAQ: OCGN) was reported by Roth Capital on June 15, 2022. The analyst firm set a price target for $8.00 expecting OCGN to rise to within 12 months (a possible 323.28% upside). 4 analyst firms have reported ratings in the last year.
罗斯资本于2022年6月15日报道了欧库根(纳斯达克：OCGN)的最新目标价。这家分析公司将目标价定为8美元，预计OCGN将在12个月内上涨至(可能上涨323.28%)。去年有4家分析公司公布了评级。
The latest analyst rating for Ocugen (NASDAQ: OCGN) was provided by Roth Capital, and Ocugen their buy rating.
罗斯资本提供了对欧库根(纳斯达克：OCGN)的最新分析师评级，欧库根给予了他们的买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocugen was filed on June 15, 2022 so you should expect the next rating to be made available sometime around June 15, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与欧库根的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Ocugen的上一次评级是在2022年6月15日提交的，所以你应该预计下一次评级将在2023年6月15日左右的某个时候提供。
While ratings are subjective and will change, the latest Ocugen (OCGN) rating was a with a price target of $0.00 to $8.00. The current price Ocugen (OCGN) is trading at is $1.89, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但Ocugen(OCGN)的最新评级为A，目标价在0.00美元至8.00美元之间。目前Ocugen(OCGN)的交易价格为1.89美元，在分析师的预测范围内。
译文内容由第三方软件翻译。